HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half year ended September 30, 2015 on Thursday, October 29, 2015 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com.
Summary of Events |
||||||
Event |
Date and Time |
Medium |
||||
Release of financial results | October 29th, after the Board Meeting |
Email, Media, Company website, Business Wire |
||||
Earnings Call | October 29th, 6.30 PM IST / 9:00 AM EDT | Hosted by the Company (Details below) | ||||
Webcast of Earnings Call |
October 29th, 6.30 PM IST / 9.00 AM EDT through Nov 2nd |
URL available on Company’s website, www.drreddys.com |
||||
Transcript of the Earnings call | Will be available on the Company’s website |
URL available on Company’s website, www.drreddys.com |
||||
Earnings Call
Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)
Audio Webcast
The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through November 2, 2015. For play back dial in phone No: 022 3065 2322, 022 61813322 and ID: 375#.
Transcript
The transcript of the earnings call will also be available on the Company’s website
Conference Dial-In Numbers |
||
Primary Number: |
+91 22 3960 0616 |
|
Secondary Number: |
+91 22 6746 5826 |
|
The numbers listed above are universally accessible from all networks and all countries. |
||
Local Access Number: |
6000 1221 3940 3977 Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune |
|
International Toll Free Number: |
USA: 1 866 746 2133 |
|
No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to accelerating access to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.
The company assumes no obligation to update any information contained herein.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151019005636/en/
CONTACT
DR. REDDY’S LABORATORIES LTD.
INVESTOR RELATIONS
KEDAR
UPADHYE, +91-40-66834297
kedaru@drreddys.com
or
MEDIA
RELATIONS
CALVIN PRINTER, +91-40-49002121
calvinprinter@drreddys.com